CASE WESTERN RESERVE UNIVERSITY

ALX Oncology's Phase 1b/2 trial results of evorpacept combined with zanidatamab in HER2-positive and HER2-low metastatic breast cancer accepted for poster spotlight at SABCS 2024, to be presented by Alberto J. Montero on Dec. 12.

Authors from various institutions collaborated on study conception, data collection, analysis, and manuscript drafting, focusing on tuberculosis research.

A study by Case Western Reserve University suggests Ozempic, containing semaglutide, may reduce Alzheimer’s risk by 40-70% in type 2 diabetes patients. Dr. Dave Montgomery highlights the potential of semaglutide to prevent Alzheimer’s by targeting brain tangles and plaques.

Semaglutide, known for treating diabetes and aiding weight loss, shows potential in reducing Alzheimer’s risk in type 2 diabetes patients, according to a study by Case Western Reserve School of Medicine. The study found a 40% to 70% lower risk of Alzheimer’s diagnosis among those prescribed semaglutide compared to other anti-diabetic drugs. Further research is needed to confirm these findings and explore semaglutide's therapeutic potential for Alzheimer’s patients.

Semaglutide, used to treat type 2 diabetes, may lower Alzheimer's risk in patients with diabetes, according to Case Western Reserve University research. The study found a 40-70% reduced risk compared to other diabetes drugs, suggesting semaglutide's potential to prevent Alzheimer's by addressing risk factors like obesity and heart disease. Further clinical trials are needed to confirm these effects.

Novo Nordisk's diabetes drug Ozempic may reduce Alzheimer's risk by 40-70% in Type 2 diabetes patients, according to a study. Semaglutide, Ozempic's active ingredient, showed lower Alzheimer's risk compared to insulin and other diabetes meds. The study highlights GLP-1 drugs' potential beyond weight loss and blood sugar regulation.

The American Academy of Ophthalmology, in partnership with FundamentalVR, launches a VR Education program supported by a $5 million grant from the Knights Templar Eye Foundation. The program, initially focusing on retinopathy of prematurity (ROP), offers a free simulation platform for ophthalmologists and trainees to enhance skills in diagnosing and treating eye diseases. The VR simulator provides training in techniques such as indirect ophthalmoscopy, laser therapy, and intravitreal injections, aiming to reduce complications in infants with ROP. The program will expand to include other areas of pediatric ophthalmology, with a desktop version available for those without VR headsets.

In metastatic hormone-sensitive prostate cancer (mHSPC), adding ¹⁷⁷Lu-PSMA-617 to androgen deprivation therapy (ADT) and chemotherapy doubled biochemical recurrence-free survival (BRFS) in the UpFrontPSMA trial. BRFS at 48 weeks increased from 16% to 41%. The median duration of freedom from castration resistance was 20 months with ¹⁷⁷Lu-PSMA-617 versus 16 months without it. Adverse events did not increase significantly with the three-drug combination.

Dr. Ravi V. Bellamkonda, a renowned biomedical engineer and higher education leader, will join Ohio State as executive VP and provost, pending Board of Trustees approval, starting January 14, 2025. He comes from Emory University, where he led initiatives in arts, AI, and student flourishing. Dr. Bellamkonda is also a distinguished researcher in biomedical engineering and a recipient of the NIH Director’s Transformative Research Award. His family, including spouse Dr. Lalita Kaligotla and dog CJ, will join him at Ohio State.

NIH launches nationwide study to understand and address the rise of type 2 diabetes in youth, aiming to identify risk factors and improve prevention and treatment strategies.